Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBOE: Omalizumab for Asthma Exacerbation Prevention
NCT05332067Phase 2Recruiting
- Sponsor
- Children's National Research Institute
- Start
- May 2022
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in asthma, sponsored by Children's National Research Institute. Started May 2022; status: recruiting.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05332067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332067.